Introduction: Leptomeningeal carcinomatosis (LMC) from non–small-cell lung cancer
(NSCLC) is a clinically important neurological complication in the era of epidermal growth …

Background Leptomeningeal carcinomatosis (LC) is a detrimental complication of patients
with non–small-cell lung cancer (NSCLC). The effect of epidermal growth factor receptor …

Background The incidence of leptomeningeal carcinomatosis (LMC) has increased in
patients with metastatic non-small cell lung cancer (NSCLC). This study aimed to evaluate …

Leptomeningeal carcinomatosis (LMC) remarkably decreases the quality of life of EGFR-
mutant lung cancer patients. In contrast to the lesions outside the central nervous system …

Objective To evaluate the influence of a first-generation epidermal growth factor receptor
tyrosine kinase inhibitor (EGFR TKI) treatment on the clinical features of leptomeningeal …

Leptomeningeal carcinomatosis occurs frequently in EGFR-mutant lung cancer, and
develops acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). This study …

Purpose We have treated patients with non-small-cell lung cancer (NSCLC) who developed
leptomeningeal metastases (LM) during gefitinib therapy, and then found symptomatic …

Abstract Introduction Leptomeningeal metastases (LMs) are associated with dismal
prognosis in NSCLC. Optimal management remains unknown in patients with EGFR …

Background After initial response to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), approximately one-third of patients develop central nervous system …

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
been successfully used to treat patients with non-small cell lung cancer (NSCLC) harboring …